ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Intraventricular treatment experience in children with central nervous system infections.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesVentriculoperitoneal (VP) shunt infections are a significant cause of morbidity and mortality in pediatric neurosurgery. Intraventricular antibiotic administration has emerged as a potential adjunctive treatment, particularly in infections caused by multidrug-resistant organisms (MDR). This study aims to evaluate the efficacy and safety of intraventricular antibiotic therapy in pediatric patients with VP shunt infections.
methodsA retrospective review was conducted on pediatric patients (0-18 years) treated with intraventricular antibiotics for VP shunt infections. Data collected included demographic characteristics, causative microorganisms, antibiotic regimens, treatment duration, clinical and microbiological outcomes, complications, and mortality.
resultsSeven patients (nine infection episodes) were included. The most frequently isolated pathogens were Enterococcus faecium, Staphylococcus haemolyticus, and Klebsiella pneumoniae. Intraventricular antibiotics used included colistin, vancomycin, tigecycline, and amikacin. CSF sterilization was achieved in 77.8% of episodes. No neurotoxic adverse effects were observed. The episode-based mortality rate was 33.3% (3/9 episodes), whereas the patient-based mortality rate was 28.6% (2/7 patients).
conclusionsIntraventricular antibiotic therapy appears to be an effective and safe adjunct in the management of VP shunt infections, particularly those caused by MDR pathogens. While CSF sterilization was achieved in most cases without neurotoxicity, systemic sepsis and comorbidities remained critical determinants of outcome. Further prospective studies are needed to standardize dosing protocols and optimize therapeutic strategies in this high-risk pediatric population.
Indexed as
Identifiers
41840269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.